We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 14, 2020

Fulvestrant 500 mg as Maintenance in HR+/HER2− Patients With Advanced Breast Cancer After First-Line Chemotherapy

The Oncologist


Additional Info

Disclosure statements are available on the authors' profiles:

The Oncologist
A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in HR-Positive, HER2-Negative Patients with Advanced Breast Cancer After First-Line Chemotherapy
Oncologist 2020 Nov 27;[EPub Ahead of Print], F Xu, Q Zheng, W Xia, Q Ouyang, D Pang, Z Yuan, Y Shi, R Peng, Q Lu, S Wang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading